Does Medicare Overpay for Prescription Drugs?

The Cato Institute
00:25:39 Report Issue
Loading transcript... Click for full transcript

Chapters & Sections (51)

0:00 Medicare Prescription Drug Spending Overview chapter 5
0:00 Medicare Prescription Drug Spending Basics
0:39 Bipartisan Budget Act and Inflation Reduction Act
1:08 Medicare Prescription Drug Pricing Debate
1:42 US Healthcare Spending and Medicare Growth
2:23 US Debt to GDP Ratio Concerns
3:05 Federal Deficits Driven by Healthcare Spending chapter 2
3:05 Federal Deficits Driven by Healthcare Spending
3:52 Federal Spending vs Revenues as Share of GDP
4:44 Medicare Prescription Drug Spending Growth Concerns chapter 3
4:44 Federal Deficits and Prescription Drug Spending
5:24 Medicare Prescription Drug Spending Growth
5:59 Medicare Prescription Drug Spending Growth Concerns
6:52 Medicare Part B Drug Pricing Comparison chapter 3
6:52 Medicare Part B Drug Pricing Comparison
7:35 Medicare Drug Pricing and Patent Exclusivity
8:15 Patent System and Drug Pricing
9:03 Optimal Pricing for Drug Innovation chapter 2
9:03 Balancing Innovation and Affordable Medication Prices
9:46 High Drug Prices Limit Innovation Benefits
10:35 Medicare Drug Price Reduction Concerns chapter 2
10:35 Concerns about High Prices and Innovation
11:04 Medicare Drug Price Reduction Efforts
12:06 Medicare Negotiation of Prescription Drug Prices chapter 2
12:06 Coverage Gap in Part D Explained
12:42 Medicare Negotiates Lower Prescription Drug Prices
13:51 Medicare's Ability to Negotiate Drug Prices chapter 3
13:51 Medicare's Ability to Negotiate Drug Prices
14:30 Medicare Negotiates Drug Prices with Pharmaceutical Companies
14:56 Negotiations between Congress and Drug Companies
15:41 Medicare Drug Pricing and Market Prices chapter 2
15:41 Critique of Central Economic Planning
16:36 Medicare Program Inflates Drug Prices Significantly
17:18 Medicare Pricing and Pharmaceutical Industry Debate chapter 3
17:18 Potential Impact of Direct Healthcare Payments
17:46 Medicare and Prescription Drug Prices
18:21 Companies Complaining About Price Reductions
18:46 Medicare Price Negotiation Impact on Innovation chapter 2
18:46 Potential Negative Impact of Price Negotiation
19:37 Medicare Price Negotiation Delayed for 60 Years
20:14 Medicare Spending Growth Projections and Inflation Reduction Act chapter 2
20:14 Medicare Prescription Drug Spending Growth Projections
20:51 Medicare Spending and Prescription Drug Prices
21:59 Healthcare Industry Lobbying and Medicare Spending chapter 3
21:59 Industry Lobbying to Defang Medicare Cuts
22:45 Healthcare Industry Influence on Capitol Hill
23:17 Lobbying Expenditures by Economic Sector
23:46 Pharmaceutical Lobby's Influence on Capitol Hill chapter 3
23:46 Lobby Influence on Capitol Hill
24:31 Fizer Ad During Super Bowl
25:02 Charles Fizer Co-Founders Relationship

Transcript

Loading transcript...